A veteran of ophthalmic research, one not typically known for his
contributions to glaucoma, will receive the Catalyst Award at Glaucoma 360 in
I am honored by the Catalyst Award. While I am best known for my
work in the fields of cornea, cataract and refractive surgery, my interest in
the management of glaucoma is longstanding, Richard L. Lindstrom, MD, OSN
Chief Medical Editor, told Ocular Surgery News.
Hosted by the Glaucoma Research Foundation, the 3-day event will bring
together leaders in research, industry, finance, clinical ophthalmology and
philanthropy, as well as representatives from the U.S. Food and Drug
Administration, in an effort to promote collaborative endeavors aimed at curing
Dr. Lindstrom will accept the Catalyst Award on the first day, at the
Glaucoma Research Foundation Annual Benefit, which seeks to raise funds in
support of innovative research, education and outreach.
The Glaucoma Research Foundations Catalyst Award honors
individuals who have advanced our knowledge of glaucoma through innovation and
collaboration. Dr. Lindstrom has shown a deep personal commitment to innovation
and has stressed that every ophthalmologist has an obligation to advance the
field, Adrienne Graves, PhD, originator of the Glaucoma 360 concept,
Dr. Lindstrom completed a 6-month fellowship in glaucoma at the
University of Utah in 1978 and has been responsible for managing cases
associated with cataract and corneal disease throughout his career.
My interest in glaucoma is now focused on minimally invasive
surgery, and I am currently working with Glaukos, Transcend and Aquesys to
bring this promising technology to market. Glaucoma is ever more prevalent as
our population ages, and I am fully supportive of the Glaucoma Research
Foundations mission to advance the art and science of this field,
Dr. Lindstrom said.
In recent years, he worked on two studies published in the Journal
of Cataract and Refractive Surgery demonstrating that patients with
glaucoma or ocular hypertension who have an IOP of 25 mm Hg or more may achieve
pressure reductions of 6 mm Hg to 8 mm Hg with phacoemulsification alone.
Dr. Lindstrom has shown strong leadership in advancing innovation
in surgical techniques, as well as playing key roles in developing new
ophthalmic drugs and devices. He has recently been lauded for championing the
need for improving regulatory processes to pave the way for continued
innovation in ophthalmology, Dr. Graves said.
Dr. Lindstroms dedication to innovative research is a key reason
he is being recognized with the Catalyst Award and will be a keynote speaker at
the meeting, which will also feature the annual CME-sponsored Glaucoma
Symposium and the New Horizons Forum promoting collaboration among medical and
corporate sectors. by Michelle Pagnani
- Poley BJ, Lindstrom RL, Samuelson TW. Long-term effects of
phacoemulsification with intraocular lens implantation in normotensive and
ocular hypertensive eyes. J Cataract Refract Surg.
- Poley BJ, Lindstrom RL, Samuelson TW, Schulze R. Intraocular
pressure reduction after phacoemulsification with intraocular lens implantation
in glaucomatous and nonglaucomatous eyes. J Cataract Refract Surg.
- Adrienne Graves, PhD, can be reached at 999 Green Street, San
Francisco, CA 94133; 707-477-5314; email:
- Richard L. Lindstrom, MD, can be reached at Minnesota Eye
Consultants, 9801 DuPont Ave. S, Suite 200, Bloomington, MN 55431;
952-888-5800; fax: 952-567-6182; email: email@example.com.
- Disclosures: Dr. Graves has no relevant financial disclosures. Dr.
Lindstrom is a consultant for Alcon, Transcend, Glaukos and Aquesys.